Azd5634 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02950805 (ClinicalTrials.gov) | May 30, 2017 | 23/8/2016 | A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis | A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis. | Pulmonary/Respiratory Diseases | Drug: Placebo;Drug: AZD5634 | AstraZeneca | Parexel | Completed | 18 Years | 60 Years | All | 9 | Phase 1 | United States |
| 2 | NCT02679729 (ClinicalTrials.gov) | February 11, 2016 | 3/2/2016 | To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration | A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects | Cystic Fibrosis | Drug: AZD5634 for inhalation;Drug: AZD5634 for infusion;Other: Placebo | AstraZeneca | NULL | Completed | 18 Years | 50 Years | All | 63 | Phase 1 | United States |